Low-dose pramlintide reduced food intake and meal duration in healthy, normal-weight subjects.
about
Molecular Structure, Membrane Interactions, and Toxicity of the Islet Amyloid Polypeptide in Type 2 Diabetes MellitusThe Effects of Lipid Membranes, Crowding and Osmolytes on the Aggregation, and Fibrillation Propensity of Human IAPPGut hormones such as amylin and GLP-1 in the control of eating and energy expenditure.Superior appetite hormone profile after equivalent weight loss by gastric bypass compared to gastric bandingAmylin activates distributed CNS nuclei to control energy balance.Effects of delayed gastric emptying on postprandial glucose kinetics, insulin sensitivity, and β-cell function.Clinical review: Regulation of food intake, energy balance, and body fat mass: implications for the pathogenesis and treatment of obesitySalmon calcitonin reduces food intake through changes in meal sizes in male rhesus monkeys.Effect of Pramlintide on Postprandial Glucose Fluxes in Type 1 Diabetes.New potential adjuncts to treatment of children with type 1 diabetes mellitus.The effects of weight loss strategies on gastric emptying and appetite control.Pharmacologic management of obesity.The interaction of amylin with other hormones in the control of eating.Effects of dietary polyphenols on neuroregulatory factors and pathways that mediate food intake and energy regulation in obesity.Rimonabant, gastrointestinal motility and obesity.Amylin receptor signaling in the ventral tegmental area is physiologically relevant for the control of food intake.Amylin-mediated control of glycemia, energy balance, and cognition.Food intake and meal pattern in IAPP knockout mice with and without infusion of exogenous IAPP.Therapy of Type 1 Diabetes Mellitus
P2860
Q26774381-DE527BA1-1ACB-4B52-B1C9-FE17A2AD95B7Q26830682-0FCB2E96-A458-4FC9-B3C7-5A1B2450D3FEQ33838133-62672817-E288-4C0E-A32F-26122A87C553Q33879265-0459D507-F8ED-4D28-BF18-9FED65166EB8Q33962500-BA245A01-76AC-49A4-9C9D-49413406B240Q34200880-C9C0DDD8-31BF-443D-BCE6-23026DD81E92Q35869629-E0110AEE-12E8-4953-AE53-4D989937A504Q36808109-9F3E352C-B729-45C9-94BC-9BD9A464B7B2Q36911451-D595189D-306B-4A8D-A75C-41AE2B9FDF6AQ37353820-26DDAF2E-347A-4587-8578-58BB41D79F98Q37897673-60440F10-9907-40D8-BC03-35EF525A0451Q37947165-5B4AC8F8-8CCD-4E4B-87CE-B3A39A825C1DQ38031993-08EC6D71-0579-4949-BBAA-E6B9B32F2184Q38057717-3C82DCD3-347B-46B0-A717-82AD5521153FQ38085530-C00128A0-D590-4FC3-8198-994F51397528Q38317203-7FDEAEF6-3EB6-4BDE-99AE-1617B18CCD0AQ38753342-CF58A973-97C6-48D0-A8A7-EB1020210686Q43866304-B64432F2-8CDA-4001-9734-32930A270567Q57412611-43128572-9A7A-473D-BBC5-B6A3CD4F392D
P2860
Low-dose pramlintide reduced food intake and meal duration in healthy, normal-weight subjects.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
2007年學術文章
@zh
2007年學術文章
@zh-hant
name
Low-dose pramlintide reduced f ...... althy, normal-weight subjects.
@en
Low-dose pramlintide reduced f ...... althy, normal-weight subjects.
@nl
type
label
Low-dose pramlintide reduced f ...... althy, normal-weight subjects.
@en
Low-dose pramlintide reduced f ...... althy, normal-weight subjects.
@nl
prefLabel
Low-dose pramlintide reduced f ...... althy, normal-weight subjects.
@en
Low-dose pramlintide reduced f ...... althy, normal-weight subjects.
@nl
P2093
P356
P1433
P1476
Low-dose pramlintide reduced f ...... althy, normal-weight subjects.
@en
P2093
Barbara Parker
Cameron W Lush
Carl Lacerte
Christian Weyer
Colleen Burns
Ian Chapman
Judith Wishart
Michael Horowitz
Robyn McKay
P2860
P304
P356
10.1038/OBY.2007.626
P577
2007-05-01T00:00:00Z